» Articles » PMID: 14767339

Verotoxin Induces Rapid Elimination of Human Renal Tumor Xenografts in SCID Mice

Overview
Journal J Urol
Publisher Wolters Kluwer
Specialty Urology
Date 2004 Feb 10
PMID 14767339
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Verotoxins (VTs) are subunit toxins produced by enteropathogenic Escherichia coli. The VT receptor glycolipid Gb3, which mediates the cytotoxicity of VTs, has been reported to be elevated on the surface of several tumor cell lines. In this study the effect of VT1 as an antineoplastic agent was assessed using various human urological cancer cell lines.

Materials And Methods: The expression of Gb3 on human cancer cell lines originating from renal cell carcinoma (ACHN, A-704, CAKI-1 and CAKI- 2), prostate cancer (LNCaP and PC3) and testicular tumor (2102Ep) were examined by FACScan (Becton Dickinson, Sunnyvale, California). These cell lines were cultured with various concentrations of VT1 and subjected to microculture tetrazolium dye assay for determination of cell viability. Furthermore, ACHN cells were inoculated into the backs of SCID mice and intratumor injection of VT1 was performed. Pathological samples were examined by hematoxylin and eosin staining as well as by TUNEL assay.

Results: The growth of ACHN, CAKI-1, A-704, 2102Ep and LNCaP but not CAKI-2 and PC3 was significantly inhibited by co-incubation with VT1, as determined by microculture tetrazolium dye assays, consistent with FACScan results for Gb3 expression. When mice bearing ACHN tumors were injected with VT1, rapid reduction in the size of subcutaneous tumors was observed with complete regression within 5 to 7 days. Pathological examination by the TUNEL method indicated that the cytotoxicity of VT1 was mediated by apoptosis.

Conclusions: These results suggest that VTs could be candidates for antineoplastic agents against Gb3 expressing tumors for clinical use.

Citing Articles

Anti-tumor Effects of Recombinant Clostridium α-Toxin on Breast Cancer: An and Study.

Rezaei Khozani N, Shayesteh Pour M, Yekani M, Hejazi S, Saffari M Int J Mol Cell Med. 2025; 13(4):404-416.

PMID: 39895919 PMC: 11786122. DOI: 10.22088/IJMCM.BUMS.13.4.404.


Shiga Toxin: Emerging Producer Strains, Prophylactic Approaches, and Application in Cancer Therapy.

Babolhavaeji K, Ahmadi A, Shokoohizadeh L J Cancer Prev. 2025; 29(4):120-128.

PMID: 39790227 PMC: 11706725. DOI: 10.15430/JCP.24.010.


AB Toxins as High-Affinity Ligands for Cell Targeting in Cancer Therapy.

Marquez-Lopez A, Fanarraga M Int J Mol Sci. 2023; 24(13).

PMID: 37446406 PMC: 10343017. DOI: 10.3390/ijms241311227.


Novel lectin-based chimeric antigen receptors target Gb3-positive tumour cells.

Melendez A, Velasco Cardenas R, Lagies S, Strietz J, Siukstaite L, Thomas O Cell Mol Life Sci. 2022; 79(10):513.

PMID: 36097202 PMC: 9468074. DOI: 10.1007/s00018-022-04524-7.


The choanoflagellate pore-forming lectin SaroL-1 punches holes in cancer cells by targeting the tumor-related glycosphingolipid Gb3.

Notova S, Bonnardel F, Rosato F, Siukstaite L, Schwaiger J, Lim J Commun Biol. 2022; 5(1):954.

PMID: 36097056 PMC: 9468336. DOI: 10.1038/s42003-022-03869-w.